Beta Bionics Inc (NASDAQ: BBNX)’s stock price has gone decline by -9.38 in comparison to its previous close of 17.81, however, the company has experienced a -23.03% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-02-27 that IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s fourth quarter and full year 2024 performance.
Is It Worth Investing in Beta Bionics Inc (NASDAQ: BBNX) Right Now?
Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BBNX is 34.77M, and currently, short sellers hold a 2.72% ratio of that floaft. The average trading volume of BBNX on March 10, 2025 was 616.95K shares.
BBNX’s Market Performance
The volatility ratio for the week is 11.54%, and the volatility levels for the past 30 days are at 6.85% for BBNX. The simple moving average for the past 20 days is -21.55% for BBNX’s stock, with a -23.83% simple moving average for the past 200 days.
Analysts’ Opinion of BBNX
Many brokerage firms have already submitted their reports for BBNX stocks, with Stifel repeating the rating for BBNX by listing it as a “Buy.” The predicted price for BBNX in the upcoming period, according to Stifel is $25 based on the research report published on February 24, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see BBNX reach a price target of $26. The rating they have provided for BBNX stocks is “Overweight” according to the report published on February 24th, 2025.
Leerink Partners gave a rating of “Outperform” to BBNX, setting the target price at $28 in the report published on February 24th of the current year.
BBNX Trading at -23.83% from the 50-Day Moving Average
After a stumble in the market that brought BBNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.12% of loss for the given period.
Volatility was left at 6.85%, however, over the last 30 days, the volatility rate increased by 11.54%, as shares sank -31.23% for the moving average over the last 20 days.
During the last 5 trading sessions, BBNX fell by -23.03%, in comparison to the 20-day moving average, which settled at $20.57. In addition, Beta Bionics Inc saw -31.70% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBNX starting from Mensinger Mike, who purchase 33,350 shares at the price of $17.00 back on Jan 31 ’25. After this action, Mensinger Mike now owns 59,019 shares of Beta Bionics Inc, valued at $566,950 using the latest closing price.
Mensinger Mike, the Chief Product Officer of Beta Bionics Inc, sale 13 shares at $17.00 during a trade that took place back on Jan 31 ’25, which means that Mensinger Mike is holding 25,669 shares at $221 based on the most recent closing price.
Stock Fundamentals for BBNX
The liquidity ratio also appears to be rather interesting for investors as it stands at 4.62.
Conclusion
In a nutshell, Beta Bionics Inc (BBNX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
